Should You Buy Akebia Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Akebia Therapeutics, Inc. (AKBA) carries a solid Quality of Company rating of 6.6/10. Trading at $0.94, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 6 of 6 CirclFi valuation models project upside for Akebia Therapeutics, Inc. (AKBA) at $0.94 — the model consensus leans bullish, with a Quality Score of 6.6/10 and Value-Trap risk of 40/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Akebia Therapeutics, Inc. (AKBA) in 2026?
What Is the Bull Case vs the Bear Case for Akebia Therapeutics, Inc. (AKBA)?
| Bull case — $1.96 target (+108.8%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +86.9% across 6 bullish models from the current price of $0.94. | No active model flags significant downside for AKBA. The Value Trap score of 40/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $1.96 (+108.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Akebia Therapeutics, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. |
How Does AKBA Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: TEVA · ADCT · ANIK · ACB · MRMD · SNOA · TKNO · KOAN · PAHC · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like AKBA on Quality?
Closest companies to AKBA’s Quality of Company score of 6.6/10, across all industries.
- ACRS — Aclaris Therapeutics, Inc. (QOC 6.6) · analysis
- CNXC — Concentrix Corporation (QOC 6.6) · analysis
- WEAV — Weave Communications, Inc. (QOC 6.6) · analysis
- PYYX — Pyxus International, Inc. (QOC 6.6) · analysis
- TULP — Bloomia Holdings, Inc. (QOC 6.6) · analysis
- BDCO — Blue Dolphin Energy Company (QOC 6.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does AKBA Appear In?
So Is Akebia Therapeutics, Inc. (AKBA) Worth Buying in 2026?
Akebia Therapeutics, Inc. at $0.94 presents what our engine identifies as a high-conviction opportunity: 6 of 6 models see upside, quality stands at 6.6/10, and the median fair value of $1.76 implies +86.9% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. Akebia Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About AKBA Stock?
Should I buy AKBA stock right now?
Based on CirclFi's multi-model analysis, 6 of 6 models see upside for AKBA at $0.94. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Akebia Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 40/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (6/13 active), reducing analytical confidence; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does AKBA compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, AKBA holds a Quality Score of 6.6/10. Comparable companies include TEVA (QOC 6.7), ADCT (QOC 6.5), ANIK (QOC 6.8). The relative ranking helps investors identify whether AKBA offers better fundamental quality than alternatives in the same sector.
Is AKBA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AKBA's Quality Score of 6.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy AKBA at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $1.68 to $1.96. At $0.94, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for AKBA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad